Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.

Toyota K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Takahashi S, Sueda T.

Ann Surg Oncol. 2018 May;25(5):1202-1210. doi: 10.1245/s10434-018-6392-y. Epub 2018 Feb 28.

PMID:
29492748
2.

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM.

Cancer Res. 2017 Aug 15;77(16):4460-4471. doi: 10.1158/0008-5472.CAN-17-0015. Epub 2017 Jun 26.

3.

Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.

Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

4.

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.

Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR.

Ann Surg. 2018 Feb;267(2):364-369. doi: 10.1097/SLA.0000000000002088.

PMID:
27893535
5.

GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.

Zhou H, Telonis AG, Jing Y, Xia NL, Biederman L, Jimbo M, Blanco F, Londin E, Brody JR, Rigoutsos I.

Cell Death Dis. 2016 Jul 14;7:e2294. doi: 10.1038/cddis.2016.169.

6.

Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.

Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T.

J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):480-8. doi: 10.1002/jhbp.366. Epub 2016 Jun 23.

PMID:
27247050
7.

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.

8.

HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z.

World J Gastroenterol. 2015 Dec 14;21(46):13004-19. doi: 10.3748/wjg.v21.i46.13004.

9.

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J.

Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11.

10.

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.

Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11.

11.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

12.

Establishment and characterization of a new human gallbladder carcinoma cell line.

Sekine S, Shimada Y, Nagata T, Moriyama M, Omura T, Yoshioka I, Hori R, Matsui K, Sawada S, Okumura T, Yoshida T, Tsukada K.

Anticancer Res. 2012 Aug;32(8):3211-8.

PMID:
22843894
13.

HuR's role in gemcitabine efficacy: an exception or opportunity?

Brody JR, Gonye GE.

Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):435-44. doi: 10.1002/wrna.62. Epub 2010 Nov 30. Review.

PMID:
21957028
14.

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR.

PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455.

15.

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK.

Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6. doi: 10.1097/SLA.0b013e3181f1fd44.

PMID:
20739850
16.

HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.

Maréchal R, Van Laethem JL.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41. doi: 10.1586/era.09.119.

PMID:
19828005
17.
18.

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR.

Cancer Res. 2009 Jun 1;69(11):4567-72. doi: 10.1158/0008-5472.CAN-09-0371.

Supplemental Content

Loading ...
Support Center